Topics:

Anna Azvolinsky, PhD

Anna Azvolinsky, PhD

Freelance science writer and frequent Cancer Network and OncoTherapy Network contributor.

Follow Her on Twitter

Posts by Author

The risk of early, sudden-onset menopause in women treated for early-stage breast cancer can be reduced with goserelin, a gonadotropin-releasing hormone agonist.

Researchers have identified patient factors linked with the discontinuation of ibrutinib therapy for reasons other than disease progression.

Two clinical factors may predict PSA response to cabazitaxel in men with metastatic castration-resistant prostate cancer.

The 4Kscore blood test has been shown to accurately detect the presence of high-grade prostate cancer, according to a study presented at ASCO GU.

This slide show includes some of the top highlights from the 2015 ASCO Genitourinary Cancers Symposium, including a study that examined the risk of aggressive prostate cancer in testicular cancer survivors and more.

Intermediate-risk prostate cancer patients managed with surveillance had worse outcomes compared with low-risk prostate cancer patients managed with surveillance.

High-dose radiation therapy did not improve overall survival compared with the standard dose in stage II localized prostate cancer, but did show some benefits.

Economic factors, including household income, and racial disparities both play a role in the adherence to hormonal therapy in breast cancer patients.

A large retrospective analysis suggests the number of patients diagnosed with intermediate- and high-risk prostate cancer has increased since 2011.

A new study suggests that cancer patients do not often request unnecessary and sometimes costly tests or treatments.

Pages

By clicking Accept, you agree to become a member of the UBM Medica Community.